Amylin Pharma - Comparative Multiple Analysis

Amylin Pharma (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of Amylin Pharma

WikiWealth compares Amylin Pharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Amylin Pharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Amylin Pharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Amylin Pharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Amylin Pharma's Analysis

How does this work? The Comparative Investment Analysis determines the value of Amylin Pharma by comparing Amylin Pharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Amylin Pharma.

See the Amylin Pharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Amylin Pharma.

Also, see the Amylin Pharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Amylin Pharma's valuation conclusion for a quick summary.